Cannabis & Hemp 2025: Rescheduling, Bans & Executive Orders
As 2025 draws to a close, the cannabis and hemp industries in the United States find themselves in a state of regulatory flux that can only be described as “whiplash.” From the long-anticipated rescheduling of marijuana to sudden legislative threats against hemp products, the year has been a rollercoaster of conflicting signals. Is rescheduling finally happening? Is the hemp industry facing an existential crisis? This guide breaks down the year’s pivotal developments, exploring the executive orders, appropriations bills, and the potential future for cannabis businesses and consumers alike.
The Road to Rescheduling: A Brief History
To understand the current situation, we must look back at the momentum that began building in 2023. Under the Biden Administration, the Department of Health and Human Services (HHS) made a significant recommendation to the Drug Enforcement Agency (DEA): marijuana should be moved from Schedule I to Schedule III of the Controlled Substances Act (CSA). This was a historic acknowledgment of the potential medical benefits of cannabis, challenging decades of federal policy that categorized it alongside heroin and LSD.
By May 2024, reports surfaced that the DEA had agreed to this rescheduling. Moving marijuana to Schedule III—placing it in the same category as ketamine and Tylenol® with codeine—promised to be a game-changer. For state-legal cannabis businesses, the most immediate benefit would be the elimination of the crippling tax burden imposed by Section 280E of the Internal Revenue Code, as detailed in previous analyses on cannabis and taxes.
However, the rulemaking process stalled. The DEA’s delay created uncertainty, which deepened in November 2025. In a move that shocked the industry, Congress included language in an appropriations bill (passed to end the longest government shutdown in U.S. history) that effectively threatened the legality of many hemp products. With hemp seemingly in the crosshairs, hope for broader cannabis reform appeared to be fading.
A New Twist: The December 2025 Executive Order
Just as the outlook seemed bleakest, a major development occurred on December 18, 2025. President Trump issued an Executive Order (EO) titled “Increasing Medical Marijuana and Cannabidiol Research.” This directive explicitly recognized the medical potential of cannabis, stating that the federal government’s delay “does not serve the Americans who report health benefits from the medical use of marijuana to ease chronic pain.” It criticized the current Schedule I status for impeding research and leaving patients and doctors without adequate guidance.
Crucially, the EO also addressed the hemp controversy. The 2018 Farm Bill had legalized hemp-derived cannabinoids (containing less than 0.3% delta-9 THC), sparking a booming market for CBD products. However, the November 2025 appropriations bill introduced strict new criteria—such as package size limits and restrictions on other tetrahydrocannabinols—that would render many of these products illegal by November 2026. The EO acknowledged the potential medical benefits of CBD and directed the administration to “work with Congress to update the statutory definition of final hemp-derived cannabinoid products.” The goal is to preserve access to safe, full-spectrum CBD products while addressing health risks, potentially offering a lifeline to a reeling industry.
The EO also commanded the Attorney General to “take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III… in the most expeditious manner.” While an EO cannot itself reschedule a drug or overturn legislation, it sends a powerful signal of intent and could accelerate the administrative process.
What Rescheduling Means (and What It Doesn’t)
It is vital to temper expectations with legal reality. Rescheduling is **not** federal legalization. Schedule III drugs generally require a prescription and are not available over the counter. This model aligns with some state medical programs but clashes with the recreational “adult-use” markets operating in many states. Consequently, much of the cannabis sold legally under state laws today would remain federally illegal even after rescheduling.
This distinction has significant implications for intellectual property. As noted in analyses regarding trademark owners, federal trademark registration requires *lawful* use in commerce. Since recreational cannabis sales would likely remain federally unlawful, businesses in that sector would still be barred from federal trademark protection. However, rescheduling could open the door for the first-ever federal registrations for compliant medical cannabis products.
The Tax Implications: A Silver Lining?
The most concrete benefit of rescheduling lies in taxation. Section 280E of the Internal Revenue Code currently forbids businesses “trafficking in controlled substances” (Schedule I or II) from deducting standard business expenses. This results in effective tax rates that can exceed 70% for some cannabis companies. Moving marijuana to Schedule III would render Section 280E inapplicable, allowing businesses to operate with a normal tax structure.
However, questions remain. The effective date of rescheduling is unclear, and it is uncertain whether the IRS will allow businesses to file amended returns for past years to claim refunds. It is possible, perhaps even likely, that the relief will only apply prospectively.
Looking Ahead to 2026
The interplay between the Executive Order, the stalled DEA process, and the restrictive appropriations bill creates a complex path forward. While the EO offers hope for both medical cannabis research and the preservation of the hemp industry, the legislative threat remains. Notably, the American Hemp Protection Act of 2025 has been introduced in the House to repeal the damaging language in the appropriations bill before it takes effect in late 2026.
As the industry navigates this “regulatory whiplash,” stakeholders must stay informed and prepared for a landscape that continues to shift beneath their feet.
- 5 Things Experienced Consumers Look for When Choosing Premium Cannabis Flower - June 19, 2026
- How to Use CBD Roll-On Oil in Your Wellness Routine - June 19, 2026
- How Online Headshops Are Setting New Quality Standards for Legal Highs - June 19, 2026
